OTC Markets OTCQX - Delayed Quote USD

CSL Limited (CSLLY)

35.39 +0.39 (+1.11%)

At close: October 30 at 4:00:00 PM EDT

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases

PR Newswire 27d ago

CSLLY
+1.11%
CSL.AX
CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases

PR Newswire 27d ago

CSL.AX

CSLLY
+1.11%
CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases

CNW Group 27d ago

CSL.AX

CSLLY
+1.11%
Public Access to ANDEMBRY® (garadacimab) Expands Across Canada for the Prevention of Hereditary Angioedema (HAE) Attacks

CNW Group 1mo ago

CSL.AX

CSLLY
+1.11%
Lancet Publication Marks Important Advance in Influenza Prevention for Older Adults

PR Newswire 1mo ago

CSL.AX

CSLLY
+1.11%
Lancet Publication Marks Important Advance in Influenza Prevention for Older Adults

PR Newswire 1mo ago

CSL.AX

CSLLY
+1.11%
CSL Ltd's Dividend Analysis

GuruFocus.com 1mo ago

CSL.AX

CSLLY
+1.11%
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers

Zacks 1mo ago

UCBJY

ALPMY

ONC
CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)

PR Newswire 3mo ago

CSL.AX

CMXHF

CSLLY
+1.11%
CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union

PR Newswire 4mo ago

FME.DE

CMXHF

CSLLY
+1.11%
CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union

CNW Group 4mo ago

CSLLY
+1.11%
CSL
Should Value Investors Buy CSL Limited (CSLLY) Stock?

Zacks 5mo ago

CSL.AX

CMXHF

CSLLY
+1.11%

Performance Overview

Return	CSLLY	S&P/ASX 200 [XJO] (^AXJO)
YTD	+26.09%	+2.22%
1-Year	+23.98%	+0.29%
3-Year	+0.92%	+31.37%

U.S. markets closed

CSL Limited (CSLLY)

CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases

CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases

CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases

Public Access to ANDEMBRY® (garadacimab) Expands Across Canada for the Prevention of Hereditary Angioedema (HAE) Attacks

Lancet Publication Marks Important Advance in Influenza Prevention for Older Adults

Lancet Publication Marks Important Advance in Influenza Prevention for Older Adults

CSL Ltd's Dividend Analysis

Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers

CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)

CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union

CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union

Should Value Investors Buy CSL Limited (CSLLY) Stock?